TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Childhood cancer survival
Endpoint domain: Mortality/survival
Primary endpoint: pain at extensor tendons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: finger flexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache attack frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of sPGA score of clear or almost clear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative hemoglobin-associated signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Coma Recovery Scale-R (CRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of creatine phosphokinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Assessment of pelvic floor muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Allergen Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Weighed composite score of maximal guideline-directed medical therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery of train of four ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Recovery of tetanus 100 Hz ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Change in grade of hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fibrinogen-like-protein 1 (FGL1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TSPO expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NLRP3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Caspase-1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-1 Beta concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of documented COVID-19 infection in vaccinated patients
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of documented COVID-19 infection in non vaccinated patients
Endpoint domain: Adverse events/effects
Primary endpoint: Para stomal herniation occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical outcomes of Influenza-like Illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dermoscopic change of width of striae rubrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Captopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from administration extrapolated to the last time of quantifiable concentration (AUC[0-t]) of Captopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinite time (AUC[0-inf]) of Captopril
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tooth color measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of swallowing-induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Favorable Pathologic Response (FPR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of low-voltage or scar area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adherence to vaginal estrogen treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 50% Seizure Responder Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of moderate to severe VMS at Week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of moderate to severe VMS at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of TEAEs leading to withdrawal from study
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of serious TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Female Sexual Function Index (FSFI) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Change in International Index of Erectile Function (IIEF) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Change in Sexual Quotient (QS) at 6 months
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Accuracy of ECGI for detecting cardiac region of interest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bronchial thickness (BT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Signal strength of the bronchial wall (SB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume of bronchial edema (VO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bronchial edema (SO) signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Volume of post-surgical bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue-resident memory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the concentration-time curve of [14C]-BI 1015550 in plasma after intravenous administration (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of BI 1015550 in plasma after oral administration (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with brain dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Cognitive Bias
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Surgical Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 28-day successful extubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Warwick Edinburg Mental Wellbeing Scale (WEMWBS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in symptom severity after COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of COVID-19 symptoms experienced
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of knowledge on road traffic crashes first aid
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in attitudes on road traffic crashes first aid
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in reported practice toward first aid provision
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: 10 Meter Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change in parent rated DARB Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinician rated clinical global impressions scale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Malnutrition Status - NRS-2002 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Upper Mid-Arm Circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of pain or swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission rate: Ulcerative colitis (UC): Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical remission rate: Ulcerative colitis (UC): Crohn's disease (CD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mtb DNA prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relative change in levels of circulating myeloid-derived suppressor cells (MDSCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative change in immune cell composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kidney prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of patients with interpretable specimen retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain score on a VAS scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of caregiver self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: sexuality
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Lower extremity functional pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful endometrial ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Extended Nordic Musculoskeletal (NMQ-E)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Early evaluation of NAT efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of SC291
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (adagrasib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (adagrasib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax (adagrasib)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroticism scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with left ventricular dysfunction and/or heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Grades II-IV Acute GvHD
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of postoperative anastomosis leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes of Constant Murley Score (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Architecture Change-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Architecture Change-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle Architecture Change-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in PMN activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reoperation due to infection or diagnosed PJI
Endpoint domain: Adverse events/effects
Primary endpoint: Dyspnea 12 Tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breathlessness, Cough, and Sputum Scale (BCSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean change from baseline in the VAS score at Day 28 visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change from baseline in Fluorescein Staining at the Day 28 visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of missed working days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: self-assessed workability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sensitivity of anal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of anal cytology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration from time zero to the last concentration above the limit of quantification (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of hydroxytyrosol metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adequate thickness of the alveolar ridge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawals due to adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in muscle mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Primary Gaze Orientation for 5 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hematologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of non-hematologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended phase 2 dose for drug combination
Endpoint domain: Resource use
Primary endpoint: Children's online behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Derived health behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in participant's postprandial glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in fat mass measured by bioimpedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes from baseline in health-related quality of life measured by the SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of enrollment in lymphoma clinical research
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants remaining in clinical study until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Absolute Change in Sweat Chloride (SwCl) in mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response of Complete Response (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of achieving a clear resection margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with dose-limiting toxicities (DLTs) by dose level
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Relief of Helicobacter pylori related dyspepsia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Oral microbial abundance in preoperative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral microbial abundance in intraoperative samples prior to antiseptic irrigations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral microbial abundance in postoperative samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' prognostic understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Energy consumed in test meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline Self-Management and Transition to Adulthood Treatment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage repigmentation: Vitiligo Area Scoring Index (VASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage repigmentation: Vitiligo Extent Score (VES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage repigmentation: Photographs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Clinically Important Abnormalities in Safety Laboratory Values
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Important Abnormalities in ECG Values
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Important Abnormalities in Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Clinically Significant Abnormalities in Physical Examinations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Satisfaction Domain Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Implementation of U=U concept
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical health impacts on Thai PLHIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health impacts on Thai PLHIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual health impacts on Thai PLHIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression free overall survival
Endpoint domain: Mortality/survival
Primary endpoint: Hearing aid users satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anxiety or depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coagulation function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall survival rate at 30 months
Endpoint domain: Mortality/survival
Primary endpoint: Success rates of laparoscopic Burch colposuspension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Systolic Automated Office Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of GVHD post-infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Change in atrophic acne scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Progression-free survival rate (PFS rate)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants using symptom monitoring survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preventable hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Preventable emergency department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Criminogenic Cognition Scale (CCS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Relapse Risk Scale (RRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived Stigma of Addiction Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brief Cope Inventory (BCI)
Endpoint domain: Life impact
Endpoint subdomain: Coping strategies
Primary endpoint: pancreatic cancer sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IPMNs sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Signs and symptoms of over-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Signs and symptoms of under-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Adaptation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Aftereffect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in FGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Community mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Subcortical/basal ganglia function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain hypometabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nintedanib maximum blood concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of nintedanib maximum blood concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nintedanib total absorption (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes